Compare Amphastar Pharmaceuticals Inc (AMPH) vs Credo Technology Group Holding Ltd (CRDO) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

CRDO trades at $257.79, down 2.96% today but maintains strong bullish momentum with analyst consensus at 'Buy' (86.7% of 15 analysts). The stock shows robust fundamentals with 35.37% net income margin and triple-digit revenue growth projections for 2026. Recent earnings consistently beat expectations, and technical indicators suggest bullish momentum with support at $258 and resistance at $276.

Outlook remains positive given AI infrastructure demand and strong financial performance, though elevated valuations (P/E 102.7) and customer concentration risks warrant caution. The consensus price target of $273.33 implies 6% upside potential from current levels, supported by institutional optimism and expanding market opportunities in high-speed connectivity solutions.